Aurora Cannabis Reports Revenues Of $75.5 Million For Q3, Doesn’t Provide Net Loss Figure

Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported third quarter earnings after the bell today, electing to only file select data in the news release before the scheduled conference call. The firm reported net revenues of $75.5 million for the quarter, while not publishing an earnings per share or net loss figure. Adjusted EBITDA for the quarter was reported as being -$50.9 million for the period.

Net revenue overall was recorded as being $78.4 million, before provisions of $2.9 million were taken into account. Cannabis revenue during the quarter was $69.6 million. Of those revenues, $41.5 million was associated with the recreational cannabis market, $27.0 million was in the medical market, while the international medical cannabis market netted $4.0 million in revenues for Aurora.

In terms of associated expenses to achieve these revenues, Aurora has claimed that it is on the path to a run-rate of $40 – $45 million per quarter for selling, general and administrative expenses, despite spending a total of $80.1 million during the quarter in this expense category. Further expenditure data has not as of yet been provided.

In terms of Aurora’s cash position, the company reported $230.2 million as of March 31, an increase from December’s figure of $156.3 million. That increase was primarily driven by the company raising $206.4 million through its at-the-market offering and $22.0 million debt, which was partially offset by burning through $154.5 million during the quarter – which, unbelievably, was a significant quarter over quarter improvement.

Lastly, Aurora produced 36,207 kilograms of cannabis during the quarter, while only selling 12,729 kilograms.

Full financials have yet to be release by the company.

Aurora Cannabis last traded at $9.20 on the TSX.


Information for this briefing was found via Sedar and Aurora Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Recommended

Cambria Gold To Spin Out Mt. Margaret Copper-Gold Project Into US-Focused Entity

Two Vessels Attacked Near Strait of Hormuz Within Hours as IRGC Escalates Maritime Campaign

Related News

Aurora Cannabis: Canaccord Anticipates Q2 Revenues Of $69.5 Million

On Thursday, February 11th, Aurora Cannabis (TSX: ACB) (NYSE: ACB) is scheduled to release their...

Tuesday, February 9, 2021, 04:01:00 PM

Aurora Cannabis Converts 99% of $230 Million Convertible Debenture Into 69 Million Shares

Aurora Cannabis (TSX: ACB) (NYSE: ACB) announced this morning that their early conversion option on...

Monday, November 25, 2019, 09:37:40 AM

Cronos Group Licenses IP From Aurora Cannabis, 22nd Century Group Related To Biosynthesis

Aurora Cannabis (TSX:ACB) has reportedly entered into a licensing arrangement with 22nd Century Group (NASDAQ:...

Wednesday, December 15, 2021, 09:21:00 AM

Aurora Cannabis: The Analysts Take On The Reliva Acquisition

A week after Aurora Cannabis (TSX: ACB) (NYSE: ACB) closed their U$40 million all-share deal...

Friday, June 5, 2020, 04:08:00 PM

Aurora Cannabis Sees Revenues Decline 23% to $75.2 Million

Aurora Cannabis (TSX: ACB) (NYSE: ACB) announced its first quarter 2020 financial results after the...

Thursday, November 14, 2019, 05:44:50 PM